Stock ONCT ONCTERNAL THERAPEUTICS, INC.
Add to a list
Suspension of trading

Oncternal Therapeutics, Inc. Stock

Stocks

ONCT

US68236P2065

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-12-02 EST 		5-day change 1st Jan Change
0.5266 USD -24.11% Intraday chart for Oncternal Therapeutics, Inc. -.--% -
25-07-01 Oncternal Therapeutics, Inc. Appoints Craig R. Jalbert as CEO CI
25-07-01 Oncternal Therapeutics, Inc. Announces Management Changes CI
Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Oncternal Therapeutics, Inc.

Market Cap 1.56M 1.35M 1.24M 1.16M 2.18M 148M 2.21M 14.71M 5.72M 72.09M 5.85M 5.72M 250M P/E Ratio 2022
-1.19x
P/E Ratio 2023 -0.8x
Enterprise Value -32.38M -27.99M -25.79M -24.15M -45.29M -3.08B -45.97M -306M -119M -1.5B -122M -119M -5.19B EV / Sales 2022
-4.9x
EV / Sales 2023 -2.95x
Free-Float
90.77%
Yield 2022 *
-
Yield 2023 -
* Estimated data More valuation ratios

Latest news : Oncternal Therapeutics, Inc.

25-07-01 Oncternal Therapeutics, Inc. Appoints Craig R. Jalbert as CEO CI
25-07-01 Oncternal Therapeutics, Inc. Announces Management Changes CI
24-12-04 Oncternal Therapeutics, Inc.(NasdaqCM:ONCT) dropped from S&P TMI Index CI
24-12-01 Oncternal Therapeutics, Inc.(NasdaqCM:ONCT) dropped from NASDAQ Composite Index CI
24-11-25 Top Premarket Decliners MT
24-11-06 Oncternal Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
24-10-23 Oncternal Therapeutics Continues to Explore Strategic Alternatives CI
24-10-22 Oncternal Therapeutics, Inc. Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer CI
24-09-12 Oncternal Therapeutics, Inc. Announces Discontinue Its Clinical Trials Evaluating ONCT-534 CI
24-09-12 Oncternal Therapeutics, Inc. Announces Workforce Reduction CI
24-09-12 Oncternal Therapeutics, Inc. Announces Cessation of Salim Yazji as Chief Medical Officer, Effective as of October 1, 2024 CI
24-09-12 Sector Update: Health Care Stocks Rise in Thursday Trading MT
24-09-12 Oncternal Therapeutics Announces Exploration of Strategic Alternatives CI
More news

Analysts' recommendations: Oncternal Therapeutics, Inc.

24-09-12 Brookline Capital Downgrades Oncternal Therapeutics to Hold From Buy MT
24-04-15 HC Wainwright Cuts Oncternal Therapeutics' Price Target to $28 From $30, Keeps Buy Rating MT
23-12-04 Brookline Capital Upgrades Oncternal Therapeutics to Buy From Hold, Price Target is $2 MT
23-09-18 HC Wainwright Upgrades Oncternal Therapeutics to Buy From Neutral, Price Target is $2 MT
23-04-04 Maxim Downgrades Oncternal Therapeutics to Hold From Buy MT
More recommendations

Press Releases: Oncternal Therapeutics, Inc.

25-03-07 Oncternal Therapeutics Announces Intent to Voluntarily Delist from Nasdaq and Deregister with the SEC AQ
24-11-25 Oncternal Therapeutics : Failure to Satisfy Listing Rule Form 8 K PU
24-10-22 Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer AQ
24-09-12 Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives AQ
24-08-08 Oncternal Therapeutics: Q2 Earnings Snapshot AQ
More press releases

Course Extremes

3 years 0.53
Extreme 0.5266
 13.14
5 years 0.53
Extreme 0.5266
 111.4
10 years 0.53
Extreme 0.5266
 211.2
More quotes

Managers and Directors: Oncternal Therapeutics, Inc.

Manager TitleAgeSince
Richard Vincent DFI
 Director of Finance/CFO 63 2017-03-31
Yisrael Katz CTO
 Chief Tech/Sci/R&D Officer - 2023-06-30
Rajesh Krishnan CTO
 Chief Tech/Sci/R&D Officer 53 -
Director TitleAgeSince
David Hale CHM
 Chairman 77 2018-11-30
Dan Kisner BRD
 Director/Board Member 79 2019-06-06
William LaRue BRD
 Director/Board Member 75 2017-11-30
More insiders

Latest insider transactions

Date Insider Type Main position Quantity % Market Cap.
24-06-19
Rosemary Mazanet
Free

Director

2,200 0.0743%
24-06-19
Michael Carter
Free

Director

2,200 0.0743%
24-06-19
Dan Kisner
Free

Director

2,200 0.0743%
Transaction History

Other Biotechnology & Medical Research

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5-day change 1-year change 3-year change Capi.($)
ONCTERNAL THERAPEUTICS, INC. Stock Oncternal Therapeutics, Inc.
-24.11%-.--%-.--%-92.14% 1.56M
LONZA GROUP AG Stock Lonza Group AG
-0.35%+0.97%-15.96%-12.73% 43.03B
REVOLUTION MEDICINES, INC. Stock Revolution Medicines, Inc.
+3.11%+3.11%+274.29%+507.94% 32.71B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.22%-1.08%+14.03%-14.37% 30.29B
BEONE MEDICINES AG Stock BeOne Medicines AG
+1.62%-2.08%-4.36%+24.05% 29.4B
CELLTRION, INC. Stock Celltrion, Inc.
+4.09%+0.93%+10.83%+18.78% 25.08B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
-1.63%+2.88%+53.73%+114.36% 13.35B
ASCENDIS PHARMA A/S Stock Ascendis Pharma A/S
+1.14%+3.62% - - 13.54B
EUROFINS SCIENTIFIC SE Stock Eurofins Scientific SE
-0.40%-1.29%+6.06%+7.59% 12.97B
IONIS PHARMACEUTICALS, INC. Stock Ionis Pharmaceuticals, Inc.
-0.74%-1.62%+105.71%+76.01% 12.11B
Average -1.70%-1.28%+49.37%+69.94% 21.25B
Weighted average by Cap. +1.05%+1.48%+54.94%+97.30%
See all sector performances

Financials

2022 2023
Net sales 1.49M 1.29M 1.19M 1.11M 2.08M 142M 2.12M 14.06M 5.47M 68.92M 5.59M 5.47M 239M 785K 679K 625K 586K 1.1M 74.65M 1.11M 7.41M 2.88M 36.31M 2.95M 2.88M 126M
Net income -44.17M -38.19M -35.18M -32.95M -61.79M -4.2B -62.71M -417M -162M -2.04B -166M -162M -7.08B -39.48M -34.13M -31.44M -29.45M -55.23M -3.75B -56.05M -373M -145M -1.83B -148M -145M -6.32B
Net Debt -63.64M -55.02M -50.68M -47.47M -89.02M -6.05B -90.35M -601M -234M -2.94B -239M -234M -10.19B -33.94M -29.34M -27.03M -25.31M -47.47M -3.23B -48.19M -320M -125M -1.57B -127M -125M -5.44B
* Estimated data More financial data

Company Profile

Logo Oncternal Therapeutics, Inc.
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.
Employees
29
Sector
Biotechnology & Medical Research
More about the company

Income Statement and Estimates

More financial data
  1. Stock Market
  2. Stocks
  3. ONCT Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong